HHV8 ORF K14 Polyclonal Antibody, Cy5.5 Conjugated
Product Specifications
Background
HHV8 has been found to be associated with three different diseases observed in AIDS patients; kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.
Synonyms
NULL
Host
Rabbit
Cross Reactivity
Virus
Immunogen
111-210/348
Target
HHV8 ORF K14
Clonality
Polyclonal
Isotype
IgG
Conjugation
Cy5.5
Source
KLH conjugated synthetic peptide derived from human HHV8/ORF K14
Applications
WB, IF (IHC-P), IF (IHC-F), IF (ICC)
Purification
Purified by Protein A.
Excitation Emission
675nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Cross Reactivity Details
HHV 8 type M
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC680525-100 1x 100 µL
CD63 (MX-49.129.5), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC550017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF555 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940178-500 1x 500 µL
CD50 (ICAM-3) (186-2G9), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040276-500 1x 500 µL
TAG-72 / CA72.4 (B72.3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details